Director Share Dealings

RNS Number : 2861E

Futura Medical PLC

09 May 2013

 



For immediate release

9 May 2013

Futura Medical plc 

("Futura" or "the Company")

Director Share Dealings

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, received notification on 8 May 2013 from James Barder, the Chief Executive of the Company, that his non-beneficial interest in the Company has increased from 352,500 ordinary shares to 392,500 ordinary shares as a result of a transfer by the trust's settlor into a family trust of which Mr Barder is a trustee, of 40,000 ordinary shares at 70 pence per share on 8 May 2013.

Mr Barder's aggregate beneficial and non-beneficial holding has therefore increased from 968,830 ordinary shares to 1,008,830 ordinary shares representing 1.30% of the Company's issued share capital.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited
Phil Walker / Giles Balleny	Tel:[phone]
For media enquiries please contact:
Buchanan Communications
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

RDSUWRNROOAVRAR